ADVERTISEMENT

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

BY DEBU TRIPATHY
PUBLISHED WEDNESDAY, JUNE 5, 2013
Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.



ADVERTISEMENT
ADVERTISEMENT
$auto_registration$